What Sets Us Apart

Arpina Optimus specializes in navigating the specific nuances of the BSE SME and NSE Emerge platforms. We understand that SMEs face unique hurdles, such as limited historical data or lean management teams. Our expertise lies in transforming these agile businesses into robust public entities by applying Molecular Financial Analysis to identify and fix "structural fractures" before they reach the regulator’s desk.

Our advisory service is holistic. We don’t just offer a roadmap; we act as your outsourced corporate finance office. This includes:

• Pre-IPO Readiness: Utilizing our Molecular system to ensure the company meets all quantitative and qualitative criteria.

• Valuation Strategy: Crafting a narrative that reflects the true intrinsic value of your "financial molecules" to attract high-quality investors.

• Corporate Restructuring: Streamlining group structures for maximum transparency and efficiency.

We believe in a collaborative ecosystem. Arpina Optimus leverages deep-rooted relationships with:

• Merchant Bankers & Underwriters: To ensure smooth placement and pricing.

• Venture Capital & PE Funds: For bridge rounds and pre-IPO funding.

• Legal & Compliance Experts: To navigate the evolving SEBI and Exchange frameworks. These partnerships ensure that our clients have access to the best-in-class resources at every stage of their journey.

Our success is measured by the growth of our clients. We have a demonstrated history of delivering results, including:

• Shreenath Paper Products Limited: Successful listing on BSE SME (₹23 Cr).

• Atal RealTech Limited: Successful listing on NSE EMERGE (₹11 Cr).

• S J Logistics: Facilitated strategic pre-IPO funding.

• Current Pipeline: We are actively managing multiple DRHP filings, including Marco Secure Solutions Pune and N-Labs (Hyderabad).

We handle the heavy lifting so you can focus on running your business. Our execution process covers:

1. Diagnosis: Initial Molecular Financial audit.

2. Synthesis: Restructuring and preparing the financial narrative.

3. Documentation: Drafting the DRHP and managing regulatory queries.

4. Marketing: Roadshows and investor outreach.

5. Listing: Managing the final transition to the public markets.